2 / 13
Page 17
Notes:
ISSN:2171-6625
http://www.jneuro.comSeptember 18-19, 2017 | Dallas, USA
4
th
International Conference on
NEUROLOGY AND NEUROIMMUNOLOGY
Complement anomalies in neurodegenerative and neurodevelopmental disorders as a trackable
molecular event during the pre-clinical phase of disease development
Candace J Strang
IPPIN Biomarkers, USA
R
ecent advances on the interactions of immune pathways
andmolecules with the cells of the central nervous system
have demonstrated a striking inter-relationship. By a still
poorly understood biological signal, injured neuronal cells
come under the surveillance of immune systems designed
for destruction and clearance of foreign cells, but not for
autologous cells. This destruction of neuronal circuitry
accounts for the clinical neurological deficits observed
in behavior studies. Some diseases for which neuronal
destruction has been shown are considered “autoimmune”
diseases for the established destruction of self-designated
cells, such as SLE. Other diseases are not yet considered to be
“autoimmune”, but indeed maybe, such as schizophrenia. In
animal models, treatment with immunosuppressive agents
has been shown to be beneficial for prevention of the clinical
signs and symptoms of CNS decline. However, this approach
cannot be considered as a prophylactic therapeutic angle,
due to the profound side effects of immune suppression for
normal immune defense. We have developed an analytical
approach for the analysis of immune molecules in context
to gain a molecular preview of the initial neuronal changes
and neuroimmune interactions. We describe the application
of this approach to gain early insight into the developing
pathology of neuronal destruction. Our plan is to describe
the point of molecular pathology that precedes tissue
pathology with the aim to define a window for therapeutic
intervention where CNS decline is prevented or minimized
without complete immune collapse.
Speaker Biography
Candace J Strang has done her PhD from UCLA, USA. She is affiliated as CSO at IPPIN
Biomarkers USA. She is a Neuroscientist with extensive experience in translational
biochemistry, neuroscience, immunology, protein design and research “at the edge”
with an interdisciplinary approach to disease pathogenesis.
e:
proteinpartners@gmail.comCandace J Strang, J Neurol Neurosci, 8:5
DOI: 10.21767/2171-6625-C1-002